Topics

FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch

09:58 EDT 26 Mar 2020 | Xconomy

A multiple sclerosis drug that came to Bristol Myers Squibb via its acquisition of Celgene last year was approved Thursday but don’t expect it to reach patients any time soon. The company says the drug’s launch will be delayed due to the coronavirus pandemic. The Bristol (NYSE: BMY) drug, ozanimod (Zeposia), is one of the […]

Original Article: FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch"

Quick Search

Relevant Topics

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...